Stock-Based Compensation Expense (Tables)

6 Months Ended

Jun. 30, 2024

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Employee Awards and Non-employee Director Award Plan Activity

The Company granted the following awards (in shares):

	Three Months Ended March 31,			Three Months Ended June 30,			Six Months Ended  June 30,
	2024			2024			2024
Employee awards:
RSUs		267,990	(1)		3,205,910	(2)		3,473,900
Market RSUs		—			2,144,000	(3)		2,144,000
Non-employee director RSUs		—			280,376	(4)		280,376
Total awards issued		267,990			5,630,286			5,898,276

_________________________

(1)RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years.

(2)RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years.

(3)Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

(4)RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.

Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations

Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
RSUs and options	$	6,248	$	5,404	$	9,947	$	8,882
Employee stock purchase plan		180		176		366		353
Total	$	6,428	$	5,580	$	10,313	$	9,235